Company news
Immuneering Corporation news in 2026
Immuneering Corporation's news releases, calls and decks from 2026, newest first.
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
November 4, 2026
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
November 4, 2026
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
October 29, 2026
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
October 26, 2026
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 2, 2026
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
September 28, 2026
Immuneering to Present at the ESMO Congress 2026
September 24, 2026
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
September 10, 2026
Immuneering to Participate in Upcoming Investor Conferences
September 3, 2026
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
August 26, 2026
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026
Immuneering Corporation Announces Grants of Inducement Awards
July 17, 2026
Immuneering Appoints Andrew Gengos as Chief Financial Officer
June 15, 2026
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 1, 2026
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
April 20, 2026
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
March 17, 2026
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 6, 2026
Immuneering to Present at the Leerink Global Healthcare Conference
March 2, 2026
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
January 7, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 28 slides · September 2026